Xanamem
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
65
Countries
3
Endpoints
47
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 47 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 11 of 47 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
3
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| XanaMIAEffect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Xanamem Alzheimer’s disease | Alzheimer's disease | Ph 2/3 | Active, not recruiting | 35 | Oct 2026 | - | |
| XanADuA Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) | Xanamem Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 25 | Mar 2019 | 2 | results |
| XanaMIA-DRA Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers | Xanamem Alzheimer’s disease, MCI / preclinical Alzheimer’s | Age 50-80 | Ph 1/2 | Completed | 5 | Feb 2022 | 1 |
Showing 1-3 of 3 trials